Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ABLYF NASDAQ:ALLO NASDAQ:BOLD NASDAQ:ONCE NASDAQ:PRTO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABLYFAblynx$50.63$50.63$12.50▼$55.04$3.81B1.995,063 shsN/AALLOAllogene Therapeutics$1.16+0.4%$1.19$0.86▼$3.78$256.27M0.364.24 million shs329,418 shsBOLDBoundless Bio$1.15-50.0%$59.97$1.00▼$4.72$25.74M-1.2376,530 shs96,520 shsONCESpark Therapeutics$0.18$113.43$34.53▼$114.20$6.94M2.05891,560 shsN/APRTOProteon Therapeutics$3.16+0.6%$19.37$0.22▼$3.94$70.09M0.61.11 million shs119,228 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABLYFAblynx0.00%0.00%0.00%0.00%0.00%ALLOAllogene Therapeutics+1.77%+0.88%+4.55%-11.54%-61.15%BOLDBoundless Bio0.00%-0.87%-2.15%+8.06%-68.25%ONCESpark Therapeutics0.00%0.00%0.00%0.00%0.00%PRTOProteon Therapeutics0.00%-0.32%+3.63%-0.95%+67.02%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABLYFAblynx$50.63$50.63$12.50▼$55.04$3.81B1.995,063 shsN/AALLOAllogene Therapeutics$1.16+0.4%$1.19$0.86▼$3.78$256.27M0.364.24 million shs329,418 shsBOLDBoundless Bio$1.15-50.0%$59.97$1.00▼$4.72$25.74M-1.2376,530 shs96,520 shsONCESpark Therapeutics$0.18$113.43$34.53▼$114.20$6.94M2.05891,560 shsN/APRTOProteon Therapeutics$3.16+0.6%$19.37$0.22▼$3.94$70.09M0.61.11 million shs119,228 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABLYFAblynx0.00%0.00%0.00%0.00%0.00%ALLOAllogene Therapeutics+1.77%+0.88%+4.55%-11.54%-61.15%BOLDBoundless Bio0.00%-0.87%-2.15%+8.06%-68.25%ONCESpark Therapeutics0.00%0.00%0.00%0.00%0.00%PRTOProteon Therapeutics0.00%-0.32%+3.63%-0.95%+67.02%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABLYFAblynx 0.00N/AN/AN/AALLOAllogene Therapeutics 2.75Moderate Buy$8.44631.12% UpsideBOLDBoundless Bio 2.25Hold$3.50204.08% UpsideONCESpark Therapeutics 0.00N/AN/AN/APRTOProteon Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ALLO, BOLD, ABLYF, ONCE, and PRTO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/11/2025BOLDBoundless BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $4.008/4/2025ALLOAllogene TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform8/4/2025ALLOAllogene TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABLYFAblynx$62.73M60.74N/AN/A$2.71 per share18.68ALLOAllogene TherapeuticsN/AN/AN/AN/A$2.01 per shareN/ABOLDBoundless BioN/AN/AN/AN/A$6.76 per shareN/AONCESpark Therapeutics$64.72M0.11N/AN/A$13.15 per share0.01PRTOProteon TherapeuticsN/AN/AN/AN/A($0.06) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABLYFAblynx-$122.67MN/A0.00∞N/AN/AN/AN/AN/AALLOAllogene Therapeutics-$257.59M-$1.11N/AN/AN/AN/A-55.99%-42.75%11/6/2025 (Estimated)BOLDBoundless Bio-$65.36MN/AN/AN/AN/AN/A-44.79%-34.24%N/AONCESpark Therapeutics-$78.82M-$2.11N/AN/AN/A-358.41%-59.10%-33.13%N/APRTOProteon Therapeutics-$20.73M-$1.15N/AN/AN/AN/AN/A-118.68%N/ALatest ALLO, BOLD, ABLYF, ONCE, and PRTO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ALLOAllogene Therapeutics-$0.28-$0.23+$0.05-$0.23N/AN/A8/5/2025Q2 2025BOLDBoundless Bio-$0.75-$0.70+$0.05-$0.70N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABLYFAblynxN/AN/AN/AN/AN/AALLOAllogene TherapeuticsN/AN/AN/AN/AN/ABOLDBoundless BioN/AN/AN/AN/AN/AONCESpark TherapeuticsN/AN/AN/AN/AN/APRTOProteon TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABLYFAblynxN/AN/AN/AALLOAllogene TherapeuticsN/A8.928.92BOLDBoundless Bio0.3914.0814.08ONCESpark Therapeutics0.354.674.35PRTOProteon TherapeuticsN/A5.985.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABLYFAblynxN/AALLOAllogene Therapeutics83.63%BOLDBoundless BioN/AONCESpark Therapeutics88.37%PRTOProteon Therapeutics23.03%Insider OwnershipCompanyInsider OwnershipABLYFAblynxN/AALLOAllogene Therapeutics13.20%BOLDBoundless Bio21.10%ONCESpark Therapeutics6.00%PRTOProteon Therapeutics45.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABLYFAblynxN/A75.25 millionN/ANot OptionableALLOAllogene Therapeutics310221.88 million192.59 millionOptionableBOLDBoundless Bio20722.39 million17.66 millionNo DataONCESpark Therapeutics36838.52 millionN/ANo DataPRTOProteon Therapeutics1722.18 millionN/ANot OptionableALLO, BOLD, ABLYF, ONCE, and PRTO HeadlinesRecent News About These CompaniesProQR Therapeutics price target raised to $4 from $2.50 at ChardanNovember 9, 2024 | markets.businessinsider.comProtara Therapeutics (TARA) Earnings Dates & ReportsNovember 1, 2024 | investing.comProQR Therapeutics upgraded to Strong Buy from Outperform at Raymond JamesOctober 29, 2024 | markets.businessinsider.comPROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On MondayOctober 28, 2024 | msn.comProQR Announces Major Share Offering AgreementOctober 25, 2024 | markets.businessinsider.comSeaport raises $225m to advance portfolio of neuropsychiatric prodrugsOctober 22, 2024 | msn.comUnderstanding Neurodegenerative Disease with Prion ResearchSeptember 13, 2024 | the-scientist.comTProdrugs and patents: Enhancing therapy adherence and reducing side effectsSeptember 11, 2024 | msn.comiPhone 13 Pro vs. iPhone 16 Pro: 65+ Upgrades to ExpectSeptember 8, 2024 | macrumors.comMPS5 Pro: the latest on rumored specs, price, and release date speculationAugust 30, 2024 | techradar.comTRapport Therapeutics Seeks IPO For CNS Treatment ProgramsMay 22, 2024 | seekingalpha.comPTC Therapeutics: Q1 Earnings SnapshotApril 25, 2024 | timesunion.comTProtara Therapeutics Inc (TARA)April 24, 2024 | investing.comiPad ProFebruary 2, 2024 | macrumors.comMEsperion Therapeutics Inc ESPRNovember 5, 2023 | morningstar.comMThe Latest Analyst Ratings for Revance TherapeuticsSeptember 20, 2023 | benzinga.comENLV - Enlivex Therapeutics Ltd.June 6, 2023 | finance.yahoo.comPrelude Therapeutics Insider Trades Send a SignalMay 25, 2023 | benzinga.comGlobal Protein Therapeutics Market Report 2023: Development of Plasma Derived Therapies Drives GrowthMay 22, 2023 | benzinga.comThe best iPhone 14 Pro deals for May 2023May 18, 2023 | techradar.comTNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Tariff-Proof Retailers Making New All-time HighsBy Dan Schmidt | September 1, 2025Oracle Has Spoken: AI Changes EverythingBy Thomas Hughes | September 10, 2025Kratos Keeps Climbing After Q2, But Valuation Risk LoomsBy Leo Miller | August 18, 2025Low-Cost Global Exposure: 3 Diversified ETFs for Value InvestorsBy Nathan Reiff | September 2, 2025Palantir Insider Selling: Risk Signal or Normal Activity?By Chris Markoch | September 4, 2025ALLO, BOLD, ABLYF, ONCE, and PRTO Company DescriptionsAblynx OTCMKTS:ABLYF$50.63 0.00 (0.00%) As of 04/30/2019Ablynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company also develops ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as various auto-immune disorders; Anti-VEGF/Ang2 Nanobody that is in Phase I clinical trial for patients with solid tumors; Anti-CX3CR1 Nanobody, which is in Phase I clinical trial for treating chronic kidney diseases; ozoralizumab, which has completed Phase I/IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone-loss related disorders comprising osteoporosis and bone metastasis, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaboration and alliance agreements with Merck & Co., Inc., AbbVie, Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Eddingpharm, Novo Nordisk A/S, Novartis Pharma AG, Taisho Pharmaceutical Co., Ltd., and Sanofi S.A. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.Allogene Therapeutics NASDAQ:ALLO$1.16 +0.01 (+0.43%) As of 09:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Boundless Bio NASDAQ:BOLDAudentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.Spark Therapeutics NASDAQ:ONCESpark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company's preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.Proteon Therapeutics NASDAQ:PRTOProteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
